Pancreatic Cancer Trial, Recruiting NCT06515587 Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06515587
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (any gender) and are willing to sign a consent form after understanding what the trial involves
  • You are well enough to carry out basic daily activities, with an activity/health status score in the acceptable range (confirm with trial site)
  • You have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by tissue testing or a combination of tissue testing and medical examination
  • You are willing to have a routine blood marker test (CA19-9) and a small blood sample (2–3ml) taken to test for something called Lewis antigens, and you agree to attend follow-up appointments
  • If you do not have pancreatic cancer, you may still be able to join a separate part of the study if you are aged 18–75, willing to sign a consent form, and agree to provide a small blood sample (2–3ml) for Lewis antigen testing

Who may not be able to join:

  • You currently have another type of cancer at the same time as pancreatic cancer
  • You have pancreatic cancer but there is no clear record of your cancer treatment plan available
  • You have tested positive for HIV
  • There are other reasons the research team believes make it unsuitable for you to join (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 18017317460

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

To explore the prognosis of pancreatic cancer with the combination of the Lewis antigen test and the CA19-9 test

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov